Two studies in the Jan. 27, 2006 Cell have yielded evidence that could prove a boon for stem cell therapies aimed at patients with Parkinson’s disease and those with compromised immune systems due to intensive cancer therapy or autoimmune disease, according to researchers. The basic findings in mice revealed critical factors that determine the fate of one type of nerve cell progenitor and that set bone marrow stem cells into action.
Researchers at the Karolinska Institutet in Sweden discovered a "master determinant" that turns embryonic stem cells into bona fide dopamine neurons, brain cells that degenerate in those with Parkinson’s disease. The findings hold promise for the future of cell replacement therapy for the debilitating and incurable disease characterized by tremors, said study authors Thomas Perlmann and Johan Ericson. The results also underscore the general importance of a thorough understanding of development for producing authentic cells of a desired type from stem cells.
"The use of cell replacement therapy in the treatment of Parkinson’s disease is fraught with many problems," Perlmann said. "However, clinical trials have provided important proof of principle that transplantation of dopamine neurons might work in patients."
"Ethical and practical issues associated with transplantation of fetal dopamine neurons to patients with Parkinson’s disease has triggered intense interest in the possibility of the use of in vitro-engineered stem cells as an unlimited cellular source for transplantation," the researchers added.
To investigate whether the identification of determinants underlying the specification of dopamine neurons during development could be exploited for generating dopamine neurons from stem cells, the researchers first looked for genes expressed in the dopamine progenitor cells in the developing midbrains of embryonic mice.
The researchers uncovered two transcription factor proteins, Lmx1a and Msx1, that are selectively expressed in dopamine progenitor cells. Further study found that Lmx1, but not Msx1, is sufficient and required for the formation of dopamine neurons in the midbrains of chicks. Early activity of Lmx1a induces expression of Msx1, leading to other events important to the differentiation of these nerve cells, they show.
Moreover, the researchers report that expression of Lmx1a in embryonic stem cells results in a robust generation of dopamine neurons with a correct midbrain identity.
"We spent a lot of effort and are now confident that these are authentic dopamine neurons," Ericson said. "If we want to treat Parkinson’s patients with stem cells, it will only work if we are able to generate authentic dopamine cells."
"In the use of stem cells for therapy, it is of utmost importance to make the correct cell type," added Perlmann. "In the brain, there are at least 1000 different types of neurons, only one of which is clinically relevant to Parkinson’s disease–a fact which emphasizes the complexity of the problem. Our data establish Lmx1a and Msx1 as critical intrinsic dopamine-neuron determinants in vivo and suggest that they may be essential tools in cell replacement strategies in Parkinson’s disease."
Further study will elucidate the utility of the stem cell-derived neurons for treating rats with Parkinson’s disease, they said. The researchers will also conduct studies to examine whether the findings in animals will hold for humans.
A second group at Mount Sinai School of Medicine in New York found that the sympathetic–or "fight or flight" branch–of the nervous system plays a critical role in coaxing bone marrow stem cells into the bloodstream. So-called hematopoietic stem cells in the bone marrow are the source for blood and immune cells.
Hematopoietic stem cell transplants are now routinely used to restore the immune systems of patients after intensive cancer therapy and for treatment of other disorders of the blood and immune system, according to the National Institutes of Health. While physicians once retrieved the stem cells directly from bone marrow, doctors now prefer to harvest donor cells that have been mobilized into circulating blood.
In normal individuals, the continuous trafficking of the stem cells between the bone marrow and blood fills empty or damaged niches and contributes to the maintenance of normal blood cell formation, according to the researchers. Although it has been known for many years that the mobilization of hematopoietic stem cells can be enhanced by multiple chemicals, the mechanisms that regulate this critical process are largely unknown, they said.
One factor in particular, known as hematopoietic cytokine granulocyte-colony stimulating factor (G-CSF), is widely used clinically to elicit hematopoietic stem cell mobilization for life-saving bone marrow transplantation, said senior author of the study, Paul Frenette.
Several years ago, Frenette’s group reported that a second compound, fucoidan, which is synthesized by certain seaweeds, could also spur the stem cells into action. The group speculated that the seaweed derivative might work by imitating a similar compound, called sulfatide, naturally present in mammalian tissues.
To test the idea, the researchers examined mice lacking the enzyme responsible for making sulfatide.
"Lo and behold, mice lacking the enzyme Cgt did not mobilize hematopoietic stem cells at all when treated with the stimulating factor G-CSF or fucoidan," Frenette said. "You don’t get such dramatic results that often in science. We knew we had stumbled onto something important."
To their surprise, further study failed to connect the stalled stem cell movement to sulfatide. Rather, they found, the deficiency stemmed from a defect in the transmission of signals sent via the sympathetic nervous system. The products of Cgt contribute to the myelin sheath that coats and protects nerve cells, they explained.
Mice with other nervous system defects also exhibited a failure to mobilize bone marrow stem cells, they found. Moreover, drugs that stimulate the sympathetic nervous system restored stem cell movement into the blood stream in mice with an impaired ability to respond to norepinephrine, the signature chemical messenger of the sympathetic system.
"The nervous system plays an important role in producing signals that maintain the stem cell niche and retention in bone marrow," Frenette said.
"The new findings add another dimension of complexity to the processes involved in stem cell maintenance and mobilization and emphasize the interrelationships among the nervous, skeletal and hematopoietic systems," he added. "They all have to work together — to talk to each other — to produce blood and maintain stem cells."
The results suggest that differences in the sympathetic nervous systems of stem cell donors may explain "conspicuous variability" in the efficiency with which they mobilize hematopoietic cells into the bloodstream, the researchers said. Furthermore, drugs that alter the signals transmitted by the sympathetic nervous system to the stem cells in bone may offer a novel strategy to improve stem cell harvests for stem cell-based therapeutics, they added.
"The new findings suggest that the nervous system, which has the inherent ability to integrate information from throughout the organism, may govern the local relationship between stem cells and their niches," said Jonas Larsson and David Scadden of the Harvard Stem Cell Institute in a preview.
The unexpected findings by Frenette and his colleagues further "suggest that the pharmacological manipulation of the sympathetic nervous system may be a means of therapeutically targeting the stem cells in their niche for the purpose of either mobilization or, conversely, attracting stem cells to the niche following transplantation," they added.
###
The researchers include Elisabet Andersson, Ulrika Tryggvason, Qiaolin Deng, Zhanna Alekseenko, Johan Ericson of the Karolinska Institutet in Stockholm, Sweden; Thomas Perlmann of the Karolinska Institutet and The Ludwig Institute for Cancer Research in Stockholm, Sweden; Stina Friling of The Ludwig Institute for Cancer Research in Stockholm, Sweden; Benoit Robert of the Institut Pasteur in Paris, France; Yoshio Katayama of the Mount Sinai School of Medicine in New York, NY and Okayama University Hospital in Okayama, Japan; Michela Battista, Wei-Ming Kao, Andres Hidalgo, Anna J. Peired, and Paul S. Frenette of the Mount Sinai School of Medicine in New York, NY; Steven A. Thomas of the University of Pennsylvania in Philadelphia, PA. This work was supported by This work was supported by the Michael J. Fox Foundation, the Royal Swedish Academy of Sciences by donation from the Wallenberg Foundation, the Swedish National Research Council, the Swedish Foundation for Strategic Research, Parkinsonfonden, KI and EC network grants, and Brainstem Genetics grant QLRT-2000-01467, National Institutes of Health grants DK56638 and HL69438, National Blood Foundation Fellowship (A.H.), and an NIH training grant T32 DK07792 (W.-M. K.).
Andersson et al.: "Identification of Intrinsic Determinants of Midbrain Dopamine Neurons." Publishing in Cell 124, pages 393-405, January 27, 2006 DOI 10.1016/j.cell.2005.10.037 www.cell.com
Katayama et al.: "Signals from the Sympathetic Nervous System Regulate Hematopoietic Stem and Progenitor Cell Egress from Bone Marrow." Publishing in Cell 124, pages 407-421, January 27, 2006 DOI 10.1016/j.cell.2005.10.041 www.cell.com
